Elevance Health, IncNYSE: ELV
Health Care · Managed Health Care
$373.38
-0.81%
Vol: 519K
Research Digest
Friday, May 1, 2026
Elevance Health beats Q1 2026, raises FY guidance; faces DOJ witness access dispute and CMS sanctions deadline May 30.
Elevance Health Q1 2026 operating revenue $49.5B (+1.5% YoY) with results ahead of expectations. Raised FY adjusted EPS guidance with greater visibility for 2026. Blocking deposition of Peter Haytaian, outgoing executive who oversaw Medicare Advantage plans, days after DOJ requested testimony. CMS extended potential sanctions deadline from March 31 to May 30, 2026, regarding risk adjustment data reporting. Stock +3.3% week, +24.4% month. Completed $53.79B share buyback program.
Previous Market Intelligence
13 daysApr 30Elevance Health reports Q1 beats estimates, raises FY2026 guidance on improved visibility; net margin jumps to 3.52%.Positive▶
Elevance Health reported Q1 2026 results ahead of expectations on April 22, with operating revenue of $49.5 billion (up 1.5% YoY). The company raised full-year adjusted EPS guidance supported by greater visibility into the remainder of 2026. Net income margin expanded dramatically to 3.52% from 1.10% in the prior year quarter. Bank of America upgraded ELV to Buy with a $435 PT (from $405). Elevance continues working with CMS on Medicare Advantage data issues, with review extended to May 30. The company launched a diaper access pilot with the National Diaper Bank Network. Stock gained 3.3% over the past week and 24.4% over the past month.
Apr 16Elevance Health beats Q4 EPS; leadership shakeup amid 2026 guidance concernsMixed▶
Elevance Health reported Q4 2025 earnings beat on EPS but missed revenue; disclosed Medicaid/Medicare membership declines. Guided FY2026 below consensus due to persistent healthcare cost pressures. Broad leadership reshuffle across Health Benefits and Carelon units in March with new presidents appointed. 2027 Medicare Advantage rates finalized with higher-than-expected increases, providing forward revenue visibility. Stock +6.5% weekly, +7.7% monthly. Analyst consensus Buy with $380.67 price target (+22.58% upside).
Apr 15Q1 2026 earnings April 22; Medicare Advantage payment increase catalyzes 10% stock rally.Positive▶
Elevance Health will release Q1 2026 financial results on April 22. CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, sparking a 10% share rally on April 8. The company faces an earnings trough in 2026 with guidance for adjusted diluted EPS declining to $25.50 from $30.29 in 2025, but positioning for recovery toward 2027 target of at least 12% EPS growth. Evercore ISI initiated rating at Inline on April 8.
Apr 14Elevance Health shares rally on 2.48% Medicare Advantage rate increase for 2027 ahead of Q1 earnings on April 22.Positive▶
Elevance Health surged after CMS finalized 2.48% Medicare Advantage payment rate increase for 2027. Analysts expect Q1 EPS of $10.61 (down 11.4% YoY), targeting at least $25.50 in adjusted EPS for 2026. Evercore ISI reinstated at Inline with $345 target. CMS notified of intent to impose intermediate sanctions on MA prescription drug plan effective May 30.
Apr 13Elevance Health rallies on 2.48% 2027 Medicare Advantage rate increase; Q1 2026 earnings due April 22.Positive▶
CMS confirmed a 2.48% average rate increase for Medicare Advantage and Part D plans in 2027, driving shares up 3.17% to $312.21. Evercore ISI reinstated coverage at Inline with a $345 price target. Q4 2025 adjusted EPS of $3.33 beat consensus ($3.10), but 2026 guidance of $25.50+ trails analyst expectations of $26.90. Q1 2026 earnings set for April 22.
Apr 10Elevance benefited from 2.48% Medicare Advantage payment rate increase for 2027; Q1 2026 earnings April 22.Positive▶
Elevance Health stock surged on CMS finalized 2.48% Medicare Advantage payment rate increase for 2027, exceeding market expectations. Q1 2026 earnings release April 22, 2026. Analysts forecast EPS $10.74 down 11.4% YoY. 2026 guidance projects adjusted diluted EPS declining to $25.50 from $30.29 in 2025. BofA lifted price recommendation to $405 from $385 on April 7.
Apr 9Elevance Health surges after CMS announces 2.48% Medicare Advantage rate increase for 2027Positive▶
Elevance Health stock surged on April 7, 2026, after CMS confirmed a 2.48% average rate increase for Medicare Advantage and Part D plans in 2027. The company will report Q1 2026 results on April 22. Evercore ISI reinstated coverage at Inline with a $345 PT, while consensus among 18 analysts is Buy with a $386.59 target. The company faces earnings pressures in 2026 (guidance: $25.50 adjusted EPS) but is positioned for 12% EPS growth in 2027 per management guidance.
Apr 8Medicare Rate Increase Drives Elevance Health Stock HigherPositive▶
CMS confirmed a 2.48% average rate increase for Medicare Advantage plans in 2027, with an additional 2.5% boost from risk-adjustment changes, pushing the effective increase to ~5%. Elevance Health stock surged on the news. The company also announced leadership appointments to strengthen execution.
Apr 7Elevance Health restructures leadership across Medicare and Carelon segments ahead of Q1 earnings April 22Mixed▶
Elevance Health reshuffled leadership with Aimée Dailey named President of Government Business (Medicare, Medicaid, FGS, GRS) and Kristy Duffey joining as President of Carelon Health overseeing clinical strategy. Company expects Q1 2026 EPS of $10.61 (down 11.4% YoY) ahead of April 22 earnings. ELV partnered with National Diaper Bank Network for 12-month pilot expanding family health access. Stock underperformed 52 weeks (-30%) versus S&P 500 (+22%). Among 21 analysts, 12 rate Strong Buy, 9 Hold with average target of $386.59 (34.95% upside). CMS sanctions threaten Medicare Advantage plans.
Apr 6Elevance Health reaffirms 2026 guidance amid CMS sanctions and leadership reshufflesPositive▶
Elevance Health reaffirmed full-year 2026 guidance: $22.30+ diluted EPS (including ~$3.20 unfavorable items), $25.50+ adjusted EPS, 90.2% ±50bp benefit expense ratio. Leadership changes: Mark Kaye expanded CFO role to oversee Carelon; Felicia Norwood leads consolidated Health Benefits; Aimée Dailey named President Government Business; Kristy Duffey joins as President Carelon Health. Elevance and National Diaper Bank launched 12-month pilot distributing free diapers to up to 75 families/month at 10 Welcome Rooms (reaching ~9,000 families in 2026). CMS disclosed plans to sanction Medicare Advantage-Prescription Drug plans over risk adjustment data issues (late Feb/early March). Q1 2026 earnings April 22 at 6 a.m. EDT with 8:30 a.m. call. Stock up $0.26 after-hours at $300.74 (+0.75%). Analyst consensus Buy with $386.59 target (+34.95% upside).
Apr 3Elevance Health appoints new leaders across Health Benefits and Carelon; CMS Medicare Advantage sanctions loom.Negative▶
Elevance Health announced leadership appointments including Aimée Dailey as President of Government Business and Kristy Duffey as President of Carelon Health. Company targets 2026 adjusted EPS of at least $25.50. However, CMS announced planned sanctions that would halt new enrollment in Medicare Advantage plans. Q1 2026 earnings call scheduled for April 22.
Apr 2Elevance Health faces CMS sanctions amid Medicare Advantage rate pressureNegative▶
Elevance Health announces leadership reshuffling amid Medicare Advantage reimbursement rate pressure for 2027; CMS intermediate sanctions imposed.
Apr 1Elevance Health announces leadership appointments while facing CMS Medicare Advantage sanctions.Mixed▶
Elevance Health announced major leadership changes on March 31, 2026. The company faces CMS sanctions that would halt new Medicare Advantage enrollment. Q1 2026 results expected April 22. Analysts maintain Buy consensus with PT of $386.59 (35% upside).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $370.09 | -0.11% | +31.7% | 17.9x | 0.41 | $336.5B |
| ELVELEVANCE | $373.38 | -0.81% | +24.4% | 12.9x | 0.50 | $81.7B |
| HUMHUMANA | $234.67 | -0.75% | +29.4% | 15.5x | 0.45 | $28.4B |
| CNCCENTENE | $53.45 | -0.45% | +51.7% | 12.3x | 0.59 | $26.5B |
| MOHMOLINA | $192.82 | -0.92% | +35.8% | 21.9x | 0.55 | $10.1B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.